



Developmental Medicine & Child Neurology

DISCLOSURE OF INTERESTS

Manuscript Number (if known):

Manuscript title: Beta-hydroxybutyrate levels in children treated with the classical ketogenic diet for drug-resistant epilepsy

All authors must sign the Disclosure of Interests form.

Author Disclosures

Any competing interest of any the authors must be declared. The aim of the statement is not to eradicate competing interests, as they are almost inevitable. Papers will not be rejected because there is a competing interest.

Name	Signature	Date	Competing Interest to Declare	
			Yes	No
1. Xiaoying Qiao	1. <i>Xiaoying Qiao</i>	19 June 2020		No
2. Li Chen	2. <i>Li Chen</i>	19 June 2020		No
3. Zimeng Ye	3. <i>Zimeng Ye</i>	19 June 2020		No
4. Dezhi Cao	4. <i>Dezhi Cao</i>	19 June 2020		No
5. Zhibin Chen	5. <i>Zhibin Chen</i>	21 June 2020	Yes	
6. Patrick Kwan	6. <i>Patrick Kwan</i>	21 June 2020	Yes	
7. Ingrid E. Scheffer	7. <i>Ingrid E. Scheffer</i>	19 June 2020	Yes	
8. Jiong Qin	8. <i>Jiong Qin</i>	21 June 2020		No
9. Jianxiang Liao	9. <i>Jianxiang Liao</i>	19 June 2020	Yes	

If none of the authors have interests to declare, the following statement will be added to their paper "The authors have stated that they had no interests which might be perceived as posing a conflict or bias."

If you have ticked 'Yes', please insert your disclosure statements in the box below.

I. E.S has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia and Xenon Pharmaceuticals; editorial boards of the *Annals of Neurology*, *Neurology and Epileptic Disorders*; may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies, has received speaker honoraria from GlaxoSmithKline, Athena Diagnostics, UCB, BioMarin, Biocodex, Eisai and Transgenomics; has received funding for travel from Athena Diagnostics, UCB, Biocodex, GlaxoSmithKline, Biomarin and Eisai. The other authors of this manuscript have no conflicts of interests to disclose.

II. J.L has served on scientific advisory boards for Zeneca, get grant from Shenzhen government.

III. Z.C.is supported by the Public Health Early Career Fellowship(GNT1156444) from National Health and Medical Research Council(NHMRC) of Australia.He also received research grant from UCB pharma and consultancy fee from Arvelle Therapeutics.

IV. P.K. is supported by a Medical Research Future Fund from the NHMRC of Australia (MRF1136427). He/his institution has received speaker or consultancy fees and/or research grants from Biscayne, Eisai, GW Pharmaceuticals, LivaNova, Novartis, UCB Pharma and Zynerva.

The other authors of this manuscript have no conflicts interests to disclose.